|Bid||35.84 x 11300|
|Ask||35.85 x 4300|
|Day's Range||35.77 - 36.12|
|52 Week Range||29.83 - 36.21|
|PE Ratio (TTM)||26.22|
|Dividend & Yield||1.28 (3.61%)|
|1y Target Est||N/A|
One biopharma's loss is another biopharma's gain when it comes to rare disease drug trials.
Bernstein sees opportunity in a buyout target.
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.